Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07288970

ACB With S-ESPB Versus ACB With iPACK for Knee Arthroplasty

This study will compare two regional anesthesia strategies for pain management after total knee arthroplasty in adults. Both strategies use an adductor canal block (ACB) to provide analgesia while preserving quadriceps muscle strength. The ACB is then combined with either a sacral erector spinae plane block (S-ESPB) or an iPACK (infiltration between the popliteal artery and the posterior capsule of the knee) block to improve posterior knee analgesia.

All patients will receive an ultrasound-guided adductor canal block with 20 mL of 0.2% ropivacaine. They will then be randomly assigned to one of two groups:

Group 1: ACB combined with a sacral erector spinae plane block (S-ESPB) using 20 mL of 0.2% ropivacaine.

Group 2: ACB combined with an iPACK block using 20 mL of 0.2% ropivacaine. Both techniques aim to provide effective postoperative analgesia while minimizing motor blockade and allowing for early mobilization. It is not known whether combining ACB with S-ESPB or with iPACK provides superior pain control, reduces opioid requirements, or results in better functional recovery after total knee arthroplasty.

The main purpose of this study is to compare the time to first rescue analgesia and overall postoperative pain control between the two regional anesthesia strategies. The study will also evaluate opioid consumption, motor function, functional mobility, side effects, and block-related complications.

We hypothesize that both combinations will provide effective analgesia, but their impact on pain intensity, duration of analgesia, and functional recovery may differ.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Poznan University of Medical Sciences

Poznan, 62-701, Poland

Location status: Recruiting

Location contact

Malgorzata Reysner, M.D. Ph.D.

CONTACT

[email protected]

+48 61 873 83 03

About this study

Total knee arthroplasty (TKA) is associated with significant postoperative pain, which can limit early mobilization, delay rehabilitation, and increase opioid use. Inadequate pain control may lead to complications such as decreased range of motion, prolonged hospitalization, and reduced patient satisfaction. Regional anesthesia techniques are a cornerstone of multimodal analgesia protocols for TKA.

The adductor canal block (ACB) is a motor-sparing technique that targets the saphenous nerve and nerve to vastus medialis while largely preserving quadriceps strength. However, ACB alone may not provide sufficient analgesia for posterior knee structures. To address this limitation, it is often combined with other blocks that target posterior knee innervation.

The iPACK (infiltration between the popliteal artery and the posterior capsule of the knee) block is designed to anesthetize the articular branches supplying the posterior capsule of the knee without causing significant motor block. The sacral erector spinae plane block (S-ESPB) is a more proximal truncal block, which may provide analgesia to the posterior knee and surrounding structures through spread of local anesthetic in the fascial planes.

This randomized controlled trial will compare two regional anesthesia strategies in patients undergoing total knee arthroplasty:

Adductor canal block (ACB) combined with sacral erector spinae plane block (S-ESPB).

Adductor canal block (ACB) combined with iPACK block. In both groups, 20 mL of 0.2% ropivacaine will be used for each block (ACB + S-ESPB or ACB + iPACK). All patients will receive standard perioperative care and multimodal analgesia according to institutional protocols.

The primary outcome of the study is the time to first rescue analgesia within 48 hours after surgery. Secondary outcomes include pain intensity at rest and during movement, total opioid consumption, motor function (quadriceps strength), postoperative nausea and vomiting, hemodynamic events, block-related complications, time to first mobilization, and patient satisfaction with pain management.

The study aims to determine whether combining ACB with S-ESPB or with iPACK results in better analgesia and functional outcomes after TKA. The results may help optimize regional anesthesia protocols for total knee arthroplasty and improve postoperative recovery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 65 years or older
  • Scheduled for elective unilateral total knee arthroplasty under spinal or general anesthesia
  • ASA physical status I-III
  • Planned use of regional anesthesia with an adductor canal block as part of multimodal analgesia
  • Ability to communicate pain intensity using the NRS scale
  • Written informed consent obtained from the patient

Exclusion criteria

  • Refusal or inability to provide informed consent
  • Allergy, intolerance, or contraindication to local anesthetics (ropivacaine)
  • Pre-existing significant neurological deficit or neuropathy in the operative limb
  • Coagulopathy or anticoagulation that contraindicates peripheral nerve blocks (e.g., INR >1.5, platelets <100,000/µL, or therapeutic anticoagulation that cannot be safely paused)
  • Infection at or near the planned needle insertion sites
  • Severe hepatic or renal impairment
  • Chronic opioid therapy (>30 days of daily opioid use before surgery)
  • Cognitive impairment or delirium preventing reliable pain assessment BMI > 40 kg/m² (optional - if chcesz ograniczyć ze względu na trudność USG)
  • Previous knee arthroplasty on the same side or revision TKA (jeśli chcesz tylko primary TKA)
  • Pregnancy or breastfeeding
  • Participation in another interventional clinical trial within 30 days

Treatment and study plan

Adductor canal block

Procedure

Ultrasound-guided adductor canal block performed with 20 mL of 0.2% ropivacaine injected around the saphenous nerve within the adductor canal. Used in both study arms as part of the regional anesthesia protocol for total knee arthroplasty.

Other names: ACB

Sacral Erector Spinae Plane Block

Procedure

Ultrasound-guided sacral erector spinae plane block performed with 20 mL of 0.2% ropivacaine injected deep to the erector spinae muscle at the sacral level. Used in combination with ACB in the ACB + S-ESPB group.

Other names: S-ESPB; Sacral ESP block

IPACK block

Procedure

Ultrasound-guided iPACK block performed with 20 mL of 0.2% ropivacaine injected between the popliteal artery and the posterior capsule of the knee. Used in combination with ACB in the ACB + iPACK group.

Other names: Infiltration between the popliteal artery and the posterior capsule of the knee

Primary outcomes

  1. Time to First Rescue Analgesia

    Time frame: Within 48 hours after surgery.

    Time (in hours) from completion of the regional blocks to the first administration of a rescue analgesic (opioid or non-opioid) given for pain intensity ≥4 on the 0-10 Numerical Rating Scale (NRS).

Secondary outcomes

  1. Pain Intensity at Rest (NRS 0-10)

    Time frame: 4 hours after surgery.

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

  2. Pain Intensity at Rest (NRS 0-10)

    Time frame: 8 hours after surgery.

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

  3. Pain Intensity at Rest (NRS 0-10)

    Time frame: 12 hours after surgery.

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

  4. Pain Intensity at Rest (NRS 0-10)

    Time frame: 24 hours after surgery.

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

  5. Pain Intensity at Rest (NRS 0-10)

    Time frame: 48 hours after surgery.

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

  6. Pain Intensity During Movement (NRS 0-10)

    Time frame: 4 hours after surgery.

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

  7. Pain Intensity During Movement (NRS 0-10)

    Time frame: 8 hours after surgery.

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

  8. Pain Intensity During Movement (NRS 0-10)

    Time frame: 12 hours after surgery.

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

  9. Pain Intensity During Movement (NRS 0-10)

    Time frame: 24 hours after surgery.

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

  10. Pain Intensity During Movement (NRS 0-10)

    Time frame: 48 hours after surgery.

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

  11. Total Opioid Consumption

    Time frame: 0-48 hours after surgery.

    Cumulative dose of opioids converted to oral morphine milligram equivalents (MME).

  12. Motor Function (Quadriceps Strength, MRC Scale)

    Time frame: 4 hours after surgery.

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

  13. Motor Function (Quadriceps Strength, MRC Scale)

    Time frame: 8 hours after surgery.

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

  14. Motor Function (Quadriceps Strength, MRC Scale)

    Time frame: 12 hours after surgery.

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

  15. Motor Function (Quadriceps Strength, MRC Scale)

    Time frame: 24 hours after surgery.

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

  16. Motor Function (Quadriceps Strength, MRC Scale)

    Time frame: 48 hours after surgery.

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

  17. Incidence of Postoperative Nausea and Vomiting (PONV)

    Time frame: 0-48 hours after surgery.

    Presence of nausea or vomiting requiring antiemetic therapy. Proportion of patients with at least one episode will be recorded.

  18. Hemodynamic Adverse Events

    Time frame: From block placement until 24 hours after surgery.

    Incidence of hypotension (systolic BP <90 mmHg or >30% decrease from baseline) and bradycardia (HR <50/min) requiring treatment.

  19. Block-Related Adverse Events

    Time frame: From block placement until 30 days after surgery.

    Incidence of complications related to the regional blocks, including prolonged sensory or motor deficit, nerve injury (evaluated in outpatient clinic if required), hematoma, infection at the injection site, persistent weakness, or local anesthetic systemic toxicity.

Study contacts

Contact information is provided by the study sponsor or research team.

Malgorzata Reysner, MD PhD

CONTACT

[email protected]

+48618738313

Sponsors and collaborators

Lead sponsor

Poznan University of Medical Sciences

Other

Registry information

Official study title

Comparison of Adductor Canal Block Combined With Sacral Erector Spinae Plane Block Versus Adductor Canal Block Combined With iPACK Block in Patients Undergoing Total Knee Arthroplasty: A Randomized Controlled Tria

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 17, 2025
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.